However, physicians should discuss other treatment options instead of strong CYP2D6-inhibiting SSRIs with their patients with breast cancer on tamoxifen that need to start with antidepressive therapy, given the biological rationale and the results from one previous well-designed epidemiological study [20]. Here, CYP2D6 is linked to breast cancer.